ResApp Appoints Non-Executive Director
Brisbane, Australia, 29 December 2017 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce the appointment of Mr Nathan Buzza as a Non-Executive Director, effective immediately. Mr Buzza is an experienced senior executive and director with 25 years’ experience in software, electronics and medical technology.
Mr Buzza was the founder of Commtech Wireless, a highly successful clinical middleware provider with offices in Australia, the United States, Europe and Asia. In 2008, Mr Buzza negotiated the trade sale of Commtech Wireless to Amcom Software and continued as General Manager for 18 months post acquisition. During Mr Buzza’s tenure, the business was listed by BRW as one of the fastest growing privately held companies in Australia for three consecutive years and the recipient of numerous accolades including the Telstra Small Business of the Year Award. In 2010, Amcom Software was acquired by Spok for US$163.8m. Mr Buzza was awarded the “Entrepreneur of the Year” from Ernst & Young in 2005 and received the Western Australian IT and Telecommunications Lifetime Achievement Award for his contribution to the IT community.
More recently, Mr Buzza was an Executive Director of Alcidion Group Limited (ASX:ALC), a provider of clinical decision support systems.
“I am privileged to be joining the board at such a pivotal moment in the Company’s history and help build upon the outstanding foundations that have already been laid,” said Mr Buzza.
The board has also accepted the resignation of Mr Brian Leedman who has served on the board since February 2016. Mr Leedman is a co-founder of the company and will continue in his role as Vice President, Corporate Affairs.
Dr Roger Aston, Chairman of ResApp commented, “Nathan’s appointment adds significant software and healthcare experience to the board and is demonstrative of the company’s transition to commercialisation in expectation of a successful SMARTCOUGH-C-2 clinical study. I’m pleased that Brian’s investor relations experience is being retained moving forward and would like to thank him on behalf of my fellow Directors for the outstanding contribution he has made.”
Ann: ResApp Appoints Non-Executive Director, page-2
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #